

Numerous adverse health consequences, apart from addiction, have been reported with SLT use. However, studies evaluating these effects have been conducted by only a few Parties. Regional differences have been reported for various adverse health effects of SLT.

## Oral Cancer

- Significant positive association of SLT with oral cancer demonstrated in studies and meta-analyses from India, Pakistan and Sudan.
- However, studies from Sweden and Norway do not report similar association.

## Pharyngeal Cancer

- Significant positive association demonstrated in studies from India.
- However, association not found to be significant in studies from Sweden.

## Pancreatic cancer

- Studies reported from Sweden and India with variable results.

## Oral precancerous lesions

- Leukoplakia, erythroplakia, verrucous hyperplasia shown to be associated with SLT use.
- Dose-response relationship also been demonstrated with regression on cessation of habit.

## Cardiovascular effects

- Include ischemic heart disease, stroke and other cardiovascular lesions.
- Studies conducted in Sweden, India, Pakistan, Bangladesh, Iran.
- Positive significant association of SLT use reported with fatal myocardial infarction and stroke.
- Results of studies on association of SLT with hypertension demonstrate variable association.

## Reproductive effects

- Adverse reproductive effects like still birth, preterm birth, low birth weight reported to be associated with SLT use by the mother.
- Improvement in these outcomes on cessation of SLT use reported by few authors.

Authors	Odds Ratio (95% CI)
<b>Oral Cancer</b>	
Siddiqi K et al 2015	3.43 (2.26-5.19)
<b>Pharyngeal Cancer</b>	
Siddiqi K et al 2015	2.23 (1.55-3.20)
<b>Esophageal Cancer</b>	
Siddiqi K et al 2015	2.17 (1.70-2.78)
<b>Pancreatic Cancer*</b>	
Alguacil & Silverman 2004	1.1 (0.4-3.1)
Boffetta et al 2005	1.60 (1.00-2.55)
Luo et al 2007	2.1 (1.2-3.6)
Hassan et al 2007	0.6 (0.3-1.4) chewing 0.5 (0.1-1.5) snuff
Pednekar 2011	1.95 (0.68-5.54)
<b>Cervical Cancer*</b>	
Simen-Kapeu et al 2009	5.5 (2.1-14)
<b>Stomach Cancer</b>	
Sinha et al 2016	1.31 (0.92-1.87)
<b>Ischemic Heart Disease</b>	
Siddiqi et al 2015	1.13 (0.94-1.36)
Vidyasagar et al 2016	1.14 (0.92-1.42)
<b>Stroke</b>	
Vidyasagar et al 2016	1.01 (0.90-1.13)
<b>Diabetes*</b>	
Ostenson et al 2012	3.3 (1.4-8.1)
Carlsson et al 2017	1.15 (1.00-1.32)
Rasouli et al 2017	1.00 (0.47-2.11)
<b>Reproductive effects *</b>	
<b>Low birth weight</b>	
Deshmukh et al 1998	2.49 (1.34-4.61)
Gupta et al 2004	1.61 (1.11-2.35)
Steyn et al 2006	0.90 (0.44-1.82)
Pratinidhi et al 2010	2.40 (1.52-3.80)
<b>Preterm birth</b>	
England et al 2003	1.32 (1.21-1.45)
Gupta et al 2004	1.61 (1.13-2.29)
Pratinidhi et al 2010	1.38 (0.78-2.43)
England et al 2013	1.44 (0.99-2.11)
<b>Stillbirth</b>	
England et al 2003	1.60 (1.15-2.21)
Gupta et al 2004	3.07 (1.67-5.68)
Pratinidhi et al 2010	4.57 (1.13-18.43)

Data from case control or cohort studies since no global meta-analysis is currently available on the topic.

**Table 1: Global Data on Smokeless Tobacco Use and Adverse Health Effects**

<b>Authors</b>	<b>Odds Ratio (95% CI)</b>
<b>Upper aerodigestive tract cancer</b>	
Sinha et al 2016	2.17 (1.47-3.22)
<b>Stomach cancer</b>	
Sinha et al 2016	1.33 (1.12-1.59)
<b>Cervical cancer</b>	
Sinha et al 2016	2.07 (1.64-2.61)
<b>Ischemic Heart Disease</b>	
Boffetta et al 2009	1.17 (1.09-1.25)
Vidyasgaran et al 2016	1.15 (1.01-1.30)
Sinha et al 2016	1.10 (1.04-1.17)
<b>Stroke</b>	
Boffetta et al 2009	1.44 (1.31-1.59)
Vidyasagaran et al 2016	1.39 (1.29-1.49)
<b>Sinha et al 2016</b>	<b>1.37 (1.24-1.51)</b>

**Table 2: Global Data on Association of Smokeless Tobacco Use and Cause-Specific Mortality**